Circassia Pharmaceuticals PLC (LON:CIR) has been assigned an average recommendation of “Buy” from the six analysts that are covering the firm. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is GBX 145 ($1.79).
CIR has been the topic of a number of recent research reports. JPMorgan Chase & Co. decreased their price objective on Circassia Pharmaceuticals PLC from GBX 170 ($2.10) to GBX 140 ($1.73) and set an “overweight” rating on the stock in a report on Wednesday, September 28th. Barclays PLC started coverage on Circassia Pharmaceuticals PLC in a report on Tuesday, June 21st. They issued an “overweight” rating and a GBX 170 ($2.10) target price on the stock. Royal Bank Of Canada downgraded Circassia Pharmaceuticals PLC to a “sector performer” rating and reduced their target price for the stock from GBX 430 ($5.32) to GBX 105 ($1.30) in a report on Tuesday, June 21st. Peel Hunt reissued an “add” rating and issued a GBX 160 ($1.98) target price on shares of Circassia Pharmaceuticals PLC in a report on Tuesday, September 27th. Finally, Numis Securities Ltd reissued a “buy” rating and issued a GBX 150 ($1.86) target price on shares of Circassia Pharmaceuticals PLC in a report on Tuesday, September 27th.
Circassia Pharmaceuticals PLC (LON:CIR) opened at 89.00 on Wednesday. The firm’s market capitalization is GBX 253.55 million. Circassia Pharmaceuticals PLC has a one year low of GBX 81.05 and a one year high of GBX 322.90. The company has a 50 day moving average price of GBX 93.95 and a 200-day moving average price of GBX 166.57.
About Circassia Pharmaceuticals PLC
Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.
Receive News & Ratings for Circassia Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.